GPCM
TRAW icon

Granite Point Capital Management’s Traws Pharma TRAW Stock Holding History

Granite Point Capital Management’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-800
Closed -$300K – 200
2021
Q1 		$300K Buy
+800
New +$302K 0.01% 171

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Granite Point Capital Management's TRAW Position: Q2 2021 in Review

Granite Point Capital Management sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 800 shares — an estimated $300K sold.

Granite Point Capital Management first reported a position in TRAW in Q1 2021 and held it in 1 quarter. The position peaked at $300K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

  • Granite Point Capital Management reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 800 Traws Pharma shares in Q2 2021, an estimated $300K.
  • Granite Point Capital Management first reported a position in Traws Pharma in Q1 2021 and held it in 1 quarter.
  • Granite Point Capital Management's Traws Pharma position peaked at $300K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on Granite Point Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.